产品名称	MMP3 Mouse mAb
别名	MMP3小鼠单克隆抗体 \| MMP3小鼠单抗
英文别名	EC 3.4.24.17 \| Matrix metalloproteinase-3 \| MMP-3 \| SL-1 \| Transin-1
规格或纯度	无载体, ExactAb™, 无叠氮钠, 已验证, 见COA
宿主种属	小鼠(Mouse)
特异性	MMP3
种属反应性	人(Human)
免疫原	Recombinant Human MMP3 Protein, C-His tag
偶联	Unconjugated

产品属性

克隆类型	单克隆抗体
克隆号	8A3-9
Format	Whole IgG
亚型	Mouse IgG1
轻链亚型	kappa
SDS-PAGE	26.2 kDa (Light Chain) & 50.0 kDa (Heavy Chain), under reducing conditions; 172.4 kDa, under non-reducing conditions.
纯化方法	Affinity chromatography
配对抗体	[Ab176193] MMP3 Mouse mAb as Capture antibody in ELISA, CLIA, LETIA
物理外观	Liquid
储存缓冲液	10mM PBS, pH7.4
防腐剂	No
浓度	见COA
储存温度	-20°C储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	37°C 下短期保存（7 天） 4°C 下短期保存（30 天）。在 -20±5°C 下长期储存（36 个月）。收货后建议分装。避免冷冻/解冻循环。
分子类型	抗体

图片

Relevance of detection results between aladdin Antibody Pair (Ab176193 & Ab176188) and Sekisui Medical in CLIA

Relevance of detection results between aladdin Antibody Pair (Ab176193 & Ab176188) and Sekisui Medical in CLIA
·Capture antibody: MMP3 Mouse mAb (Ab176193)
·Detection antibody: MMP3 Mouse mAb (Ab176188)

Binding ELISA - MMP3 Mouse mAb (Ab176188)

Binding ELISA - MMP3 Mouse mAb (Ab176188)
Immobilized Recombinant Human MMP3 Protein at 2.0 μg/mL can bind MMP3 Mouse mAb (Ab176188) with the EC₅₀ of 65.19 ng/mL.

关联靶点（人）

MMP3 Tchem 基质溶解素-1(Stromelysin-1) (0 活性数据)

点击查看靶蛋白信息： MMP3

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

MMP3 Tchem Matrix metalloproteinase 3 (3433 活性数据)

点击查看靶蛋白信息： MMP3

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

应用

应用名称	稀释比例
CLIA	100μg/4μg AE

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1011965	分析证书	24-10-14	Ab176188
ZJ23F0901177	分析证书	23-10-07	Ab176188
ZJ23F0901178	分析证书	23-10-07	Ab176188

可替换产品

参考文献

1. Natchus MG, Cheng M, Wahl CT, Pikul S, Almstead NG, Bradley RS, Taiwo YO, Mieling GE, Dunaway CM, Snider CE, McIver JM, Barnett BL, McPhail SJ, Anastasio MB, De B.. (1998) Design and synthesis of conformationally-constrained MMP inhibitors.. Bioorg Med Chem Lett, 8 (16): (2077-2080). [PMID:9873489] [10.1016/s0960-894x(98)00370-9]
2. Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE.. (2001) Heterocycle-based MMP inhibitors with P2' substituents.. Bioorg Med Chem Lett, 11 (8): (1009-1013). [PMID:11327577] [10.1016/s0960-894x(01)00137-8]
3. Gowravaram MR, Tomczuk BE, Johnson JS, Delecki D, Cook ER, Ghose AK, Mathiowetz AM, Spurlino JC, Rubin B, Smith DL.. (1995) Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group.. J Med Chem, 38 (14): (2570-2581). [PMID:7629797] [10.1021/jm00014a010]
4. Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison RK, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Hagmann WK.. (1997) Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.. J Med Chem, 40 (6): (1026-1040). [PMID:9083493] [10.1021/jm960465t]
5. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE.. (1998) Discovery of potent, achiral matrix metalloproteinase inhibitors.. J Med Chem, 41 (19): (3568-3571). [PMID:9733482] [10.1021/jm980253r]
6. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE.. (1999) Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.. J Med Chem, 42 (1): (87-94). [PMID:9888835] [10.1021/jm980142s]
7. Cheng M, De B, Almstead NG, Pikul S, Dowty ME, Dietsch CR, Dunaway CM, Gu F, Hsieh LC, Janusz MJ, Taiwo YO, Natchus MG, Hudlicky T, Mandel M.. (1999) Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.. J Med Chem, 42 (26): (5426-5436). [PMID:10639284] [10.1021/jm9904699]
8. Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S.. (2000) Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.. J Med Chem, 43 (3): (369-380). [PMID:10669564] [10.1021/jm990366q]
9. Natchus MG, Bookland RG, Laufersweiler MJ, Pikul S, Almstead NG, De B, Janusz MJ, Hsieh LC, Gu F, Pokross ME, Patel VS, Garver SM, Peng SX, Branch TM, King SL, Baker TR, Foltz DJ, Mieling GE.. (2001) Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.. J Med Chem, 44 (7): (1060-1071). [PMID:11297453] [10.1021/jm000477l]
10. Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K.. (2002) New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.. J Med Chem, 45 (4): (930-936). [PMID:11831905] [10.1021/jm010349c]
11. Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S. (2004) Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.. J Med Chem, 47 (8): (1930-8). [PMID:15055993]
12. Wu Y, Li J, Wu J, Morgan P, Xu X, Rancati F, Vallese S, Raveglia L, Hotchandani R, Fuller N et al.. (2012) Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).. Bioorg Med Chem Lett, 22 (1): (138-43). [PMID:22153340]
13. Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX. (2013) Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.. J Med Chem, 56 (11): (4357-73). [PMID:23631440]
14. Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C et al.. (2007) Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.. J Biol Chem, 282 (38): (27781-91). [PMID:17623656]
15. Georgiadis D, Yiotakis A. (2008) Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.. Bioorg Med Chem, 16 (19): (8781-94). [PMID:18790648]
16. Kwan JC, Eksioglu EA, Liu C, Paul VJ, Luesch H. (2009) Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.. J Med Chem, 52 (18): (5732-47). [PMID:19715320]
17. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.. Eur J Med Chem, 46 (7): (2617-29). [PMID:21514700]
18. Ruminski PG, Massa M, Strohbach J, Hanau CE, Schmidt M, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Shieh HS et al.. (2016) Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.. J Med Chem, 59 (1): (313-27). [PMID:26653735]
19. Jennifer A Jacobsen,Jessica L Fullagar,Melissa T Miller,Seth M Cohen. (2010-12-30) Identifying chelators for metalloprotein inhibitors using a fragment-based approach.. Journal of medicinal chemistry, 54 ((2)): (591-602). [PMID:21189019]
20. Guan-Sheng Jiao,Seongjin Kim,Mahtab Moayeri,Devorah Crown,April Thai,Lynne Cregar-Hernandez,Linda McKasson,Banumathi Sankaran,Axel Lehrer,Teri Wong,Lisa Johns,Stephen A Margosiak,Stephen H Leppla,Alan T Johnson. (2012-02-22) Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.. Bioorganic & medicinal chemistry letters, 22 ((6)): (2242-2246). [PMID:22342144]
21. Major Gooyit,Wei Song,Kiran V Mahasenan,Katerina Lichtenwalter,Mark A Suckow,Valerie A Schroeder,William R Wolter,Shahriar Mobashery,Mayland Chang. (2013-09-14) O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.. Journal of medicinal chemistry, 56 ((20)): (8139-8150). [PMID:24028490]
22. Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R.. (2004) Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.. J Med Chem, 47 (11): (2826-2832). [PMID:15139760] [10.1021/jm030386z]
23. Rizzo RC, Toba S, Kuntz ID.. (2004) A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations.. J Med Chem, 47 (12): (3065-3074). [PMID:15163188] [10.1021/jm030570k]
24. Campestre C, Agamennone M, Tortorella P, Preziuso S, Biasone A, Gavuzzo E, Pochetti G, Mazza F, Hiller O, Tschesche H, Consalvi V, Gallina C.. (2006) N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.. Bioorg Med Chem Lett, 16 (1): (20-24). [PMID:16242329] [10.1016/j.bmcl.2005.09.057]
25. Pochetti G, Gavuzzo E, Campestre C, Agamennone M, Tortorella P, Consalvi V, Gallina C, Hiller O, Tschesche H, Tucker PA, Mazza F.. (2006) Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.. J Med Chem, 49 (3): (923-931). [PMID:16451058] [10.1021/jm050787+]
26. Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV.. (2008) beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.. Bioorg Med Chem Lett, 18 (3): (1140-1145). [PMID:18083558] [10.1016/j.bmcl.2007.11.129]
27. Li JJ, Nahra J, Johnson AR, Bunker A, O'Brien P, Yue WS, Ortwine DF, Man CF, Baragi V, Kilgore K, Dyer RD, Han HK.. (2008) Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.. J Med Chem, 51 (4): (835-841). [PMID:18251495] [10.1021/jm701274v]
28. Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF.. (2008) 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.. Bioorg Med Chem Lett, 18 (1): (409-413). [PMID:17981034] [10.1016/j.bmcl.2007.10.045]
29. Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G.. (2009) Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.. J Med Chem, 52 (2): (358-368). [PMID:19093877] [10.1021/jm801052f]
30. Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB.. (2009) High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.. Bioorg Med Chem, 17 (3): (990-1005). [PMID:18358729] [10.1016/j.bmc.2008.03.004]
31. Li W, Li J, Wu Y, Wu J, Hotchandani R, Cunningham K, McFadyen I, Bard J, Morgan P, Schlerman F, Xu X, Tam S, Goldman SJ, Williams C, Sypek J, Mansour TS.. (2009) A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408).. J Med Chem, 52 (7): (1799-1802). [PMID:19278250] [10.1021/jm900093d]
32. Yan YL, Miller MT, Cao Y, Cohen SM.. (2009) Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.. Bioorg Med Chem Lett, 19 (7): (1970-1976). [PMID:19261472] [10.1016/j.bmcl.2009.02.044]
33. Monovich LG, Tommasi RA, Fujimoto RA, Blancuzzi V, Clark K, Cornell WD, Doti R, Doughty J, Fang J, Farley D, Fitt J, Ganu V, Goldberg R, Goldstein R, Lavoie S, Kulathila R, Macchia W, Parker DT, Melton R, O'Byrne E, Pastor G, Pellas T, Quadros E, Reel N, Roland DM, Sakane Y, Singh H, Skiles J, Somers J, Toscano K, Wigg A, Zhou S, Zhu L, Shieh WC, Xue S, McQuire LW.. (2009) Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.. J Med Chem, 52 (11): (3523-3538). [PMID:19422229] [10.1021/jm801394m]
34. Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A.. (2009) N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.. J Med Chem, 52 (15): (4757-4773). [PMID:19606871] [10.1021/jm900261f]
35. Li W, Li J, Wu Y, Rancati F, Vallese S, Raveglia L, Wu J, Hotchandani R, Fuller N, Cunningham K, Morgan P, Fish S, Krykbaev R, Xu X, Tam S, Goldman SJ, Abraham W, Williams C, Sypek J, Mansour TS.. (2009) Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.. J Med Chem, 52 (17): (5408-5419). [PMID:19725580] [10.1021/jm900809r]
36. Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A.. (2009) Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.. J Med Chem, 52 (20): (6347-6361). [PMID:19775099] [10.1021/jm900335a]
37. Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.. (2010) Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.. Bioorg Med Chem Lett, 20 (2): (576-580). [PMID:20005097] [10.1016/j.bmcl.2009.11.081]
38. Testero SA, Lee M, Staran RT, Espahbodi M, Llarrull LI, Toth M, Mobashery S, Chang M.. (2011) Sulfonate-containing thiiranes as selective gelatinase inhibitors.. ACS Med Chem Lett, 2 (2): (177-181). [PMID:24900296] [10.1021/ml100254e]
39. Shiozaki M, Maeda K, Miura T, Kotoku M, Yamasaki T, Matsuda I, Aoki K, Yasue K, Imai H, Ubukata M, Suma A, Yokota M, Hotta T, Tanaka M, Hase Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T.. (2011) Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.. J Med Chem, 54 (8): (2839-2863). [PMID:21417219] [10.1021/jm101609j]
40. Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M.. (2011) Selective water-soluble gelatinase inhibitor prodrugs.. J Med Chem, 54 (19): (6676-6690). [PMID:21866961] [10.1021/jm200566e]
41. Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA.. (2011) Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.. J Med Chem, 54 (13): (4350-4364). [PMID:21548582] [10.1021/jm2001025]
42. La Pietra V, Marinelli L, Cosconati S, Di Leva FS, Nuti E, Santamaria S, Pugliesi I, Morelli M, Casalini F, Rossello A, La Motta C, Taliani S, Visse R, Nagase H, da Settimo F, Novellino E.. (2012) Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.. Eur J Med Chem, 47 (143-152). [PMID:22088955] [10.1016/j.ejmech.2011.10.035]
43. Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P, Fields GB, Roush WR.. (2011) Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.. Bioorg Med Chem Lett, 21 (23): (7180-7184). [PMID:22018790] [10.1016/j.bmcl.2011.09.077]
44. De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S.. (2012) Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.. Bioorg Med Chem Lett, 22 (1): (271-277). [PMID:22153941] [10.1016/j.bmcl.2011.11.034]
45. Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I.. (2012) In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.. Bioorg Med Chem, 20 (7): (2323-2337). [PMID:22386984] [10.1016/j.bmc.2012.02.010]
46. Stierle DB, Stierle AA, Girtsman T, McIntyre K, Nichols J.. (2012) Caspase-1 and -3 inhibiting drimane sesquiterpenoids from the extremophilic fungus Penicillium solitum.. J Nat Prod, 75 (2): (262-266). [PMID:22276851] [10.1021/np200528n]
47. Gege C, Bao B, Bluhm H, Boer J, Gallagher BM, Korniski B, Powers TS, Steeneck C, Taveras AG, Baragi VM.. (2012) Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.. J Med Chem, 55 (2): (709-716). [PMID:22175799] [10.1021/jm201152u]
48. Lee M, Ikejiri M, Klimpel D, Toth M, Espahbodi M, Hesek D, Forbes C, Kumarasiri M, Noll BC, Chang M, Mobashery S.. (2012) Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.. ACS Med Chem Lett, 3 (6): (490-495). [PMID:22737278] [10.1021/ml300050b]
49. Maingot L, Elbakali J, Dumont J, Bosc D, Cousaert N, Urban A, Deglane G, Villoutreix B, Nagase H, Sperandio O, Leroux F, Deprez B, Deprez-Poulain R.. (2013) Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.. Eur J Med Chem, 69 (244-261). [PMID:24044937] [10.1016/j.ejmech.2013.08.027]
50. Sodji QH, Patil V, Kornacki JR, Mrksich M, Oyelere AK.. (2013) Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.. J Med Chem, 56 (24): (9969-9981). [PMID:24304348] [10.1021/jm401225q]
51. Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.. (2014) Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.. J Med Chem, 57 (21): (8886-8902). [PMID:25264600] [10.1021/jm500981k]
52. Spicer TP, Jiang J, Taylor AB, Choi JY, Hart PJ, Roush WR, Fields GB, Hodder PS, Minond D.. (2014) Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.. J Med Chem, 57 (22): (9598-9611). [PMID:25330343] [10.1021/jm501284e]
53. Durham TB, Klimkowski VJ, Rito CJ, Marimuthu J, Toth JL, Liu C, Durbin JD, Stout SL, Adams L, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.. (2014) Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.. J Med Chem, 57 (24): (10476-10485). [PMID:25415648] [10.1021/jm501522n]
54. Crascì L, Vicini P, Incerti M, Cardile V, Avondo S, Panico A.. (2015) 2-Benzisothiazolylimino-5-benzylidene-4-thiazolidinones as protective agents against cartilage destruction.. Bioorg Med Chem, 23 (7): (1551-1556). [PMID:25725607] [10.1016/j.bmc.2015.02.002]
55. Stierle AA, Stierle DB, Girtsman T, Mou TC, Antczak C, Djaballah H.. (2015) Azaphilones from an Acid Mine Extremophile Strain of a Pleurostomophora sp.. J Nat Prod, 78 (12): (2917-2923). [PMID:26641525] [10.1021/acs.jnatprod.5b00519]
56. Nara H, Sato K, Kaieda A, Oki H, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.. (2016) Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.. Bioorg Med Chem, 24 (23): (6149-6165). [PMID:27825552] [10.1016/j.bmc.2016.09.009]
57. Ouvry G, Berton Y, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Chambon S, Comino C, Deprez B, Duvert D, Duvert G, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Pascau J, Pinto A, Polge G, Reitz A, Reversé K, Rosignoli C, Taquet N, Hennequin LF.. (2017) Identification of novel TACE inhibitors compatible with topical application.. Bioorg Med Chem Lett, 27 (8): (1848-1853). [PMID:28274635] [10.1016/j.bmcl.2017.02.035]
58. Durham TB, Marimuthu J, Toth JL, Liu C, Adams L, Mudra DR, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.. (2017) A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.. J Med Chem, 60 (13): (5933-5939). [PMID:28613895] [10.1021/acs.jmedchem.7b00650]
59. Choi JY, Fuerst R, Knapinska AM, Taylor AB, Smith L, Cao X, Hart PJ, Fields GB, Roush WR.. (2017) Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.. J Med Chem, 60 (13): (5816-5825). [PMID:28653849] [10.1021/acs.jmedchem.7b00514]
60. Senn N, Ott M, Lanz J, Riedl R.. (2017) Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.. J Med Chem, 60 (23): (9585-9598). [PMID:28953404] [10.1021/acs.jmedchem.7b01001]
61. Baggio C, Cerofolini L, Fragai M, Luchinat C, Pellecchia M.. (2018) HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.. ACS Med Chem Lett, 9 (2): (137-142). [PMID:29456802] [10.1021/acsmedchemlett.7b00483]
62. Fuerst R, Yong Choi J, Knapinska AM, Smith L, Cameron MD, Ruiz C, Fields GB, Roush WR.. (2018) Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.. Bioorg Med Chem, 26 (18): (4984-4995). [PMID:30249495] [10.1016/j.bmc.2018.08.020]
63. Wang CG, Yao WN, Zhang B, Hua J, Liang D, Wang HS.. (2018) Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration.. Bioorg Med Chem Lett, 28 (14): (2413-2417). [PMID:29921475] [10.1016/j.bmcl.2018.06.024]
64. Liu B, Trout REL, Chu GH, McGarry D, Jackson RW, Hamrick JC, Daigle DM, Cusick SM, Pozzi C, De Luca F, Benvenuti M, Mangani S, Docquier JD, Weiss WJ, Pevear DC, Xerri L, Burns CJ.. (2020) Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.. J Med Chem, 63 (6): (2789-2801). [PMID:31765155] [10.1021/acs.jmedchem.9b01518]
65. Baggio C,Velazquez JV,Fragai M,Nordgren TM,Pellecchia M. (2020) Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.. J Med Chem, 63 (21): (12911-12920). [PMID:33107733] [10.1021/acs.jmedchem.0c01285]
66. Ogata, Y Y, Enghild, J J JJ and Nagase, H H.. (1992) Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9.. The Journal of biological chemistry, (25): [PMID:1371271]
67. Nagase, H H, Enghild, J J JJ, Suzuki, K K and Salvesen, G G.. (1990) Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate.. Biochemistry, (19): [PMID:2383557]
68. Whitham, S E SE and 9 more authors.. (1986) Comparison of human stromelysin and collagenase by cloning and sequence analysis.. The Biochemical journal, (15): [PMID:3030290]
69. Saus, J J and 5 more authors.. (1988) The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin.. The Journal of biological chemistry, (15): [PMID:3360803]
70. Wilhelm, S M SM and 7 more authors.. (1987) Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:3477804]
71. Gooley, P R PR and 9 more authors.. (1994) The NMR structure of the inhibited catalytic domain of human stromelysin-1.. Nature structural biology, [PMID:7656014]
72. Becker, J W JW and 9 more authors.. (1995) Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme.. Protein science : a publication of the Protein Society, [PMID:8535233]
73. Ye, S S and 5 more authors.. (1996) Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression.. The Journal of biological chemistry, (31): [PMID:8662692]
74. Dhanaraj, V V and 9 more authors.. (1996) X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily.. Structure (London, England : 1993), (15): [PMID:8740360]
75. Gomis-Rüth, F X FX and 11 more authors.. (1997) Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.. Nature, (4): [PMID:9288970]
76. Li, Y C YC, Zhang, X X, Melton, R R, Ganu, V V and Gonnella, N C NC.. (1998) Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor.. Biochemistry, (6): [PMID:9760240]
77. Finzel, B C BC and 12 more authors.. (1998) Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity.. Protein science : a publication of the Protein Society, [PMID:9792098]
78. Stockman, B J BJ and 18 more authors.. (1998) Solution structures of stromelysin complexed to thiadiazole inhibitors.. Protein science : a publication of the Protein Society, [PMID:9827994]
79. Pavlovsky, A G AG and 11 more authors.. (1999) X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity.. Protein science : a publication of the Protein Society, [PMID:10422833]
80. Chen, L L and 6 more authors.. (1999) Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.. Journal of molecular biology, (29): [PMID:10543949]
81. Yamada, Yoshiji Y and 8 more authors.. (2002) Prediction of the risk of myocardial infarction from polymorphisms in candidate genes.. The New England journal of medicine, (12): [PMID:12477941]
82. Becker, Daniel P DP and 17 more authors.. (2005) Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.. Journal of medicinal chemistry, (20): [PMID:16220987]
83. Choi, Dong-Hee DH and 5 more authors.. (2011) Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death.. The Journal of biological chemistry, (22): [PMID:21330369]
84. Durrant, Jacob D JD, de Oliveira, César A F CA and McCammon, J Andrew JA.. (2011) Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors.. Chemical biology & drug design, [PMID:21609408]
85. Qiu, Zheng Z and 7 more authors.. (2012) Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).. Journal of enzyme inhibition and medicinal chemistry, [PMID:21827363]
86. Shin, Eun Jung EJ, Kim, Eun-Mee EM, Lee, Ji Ae JA, Rhim, Hyangshuk H and Hwang, Onyou O.. (2012) Matrix metalloproteinase-3 is activated by HtrA2/Omi in dopaminergic cells: relevance to Parkinson's disease.. Neurochemistry international, [PMID:22265821]
87. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

MMP3 Mouse mAb

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

应用

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器